Keyphrases
Platelets
100%
Calpain
100%
Platelet Adhesion
100%
Glycoprotein VI
100%
P38 MAP Kinase
100%
Convulxin
57%
Collagen Peptide
57%
Phosphatidylserine Exposure
42%
Membrane Blebbing
42%
Ca(II)
28%
Fibrinogen
28%
P38 Mitogen-activated Protein Kinase (p38 MAPK)
28%
Collagen
14%
Phosphorylation
14%
Helsinki
14%
Finland
14%
Protease Inhibitors
14%
Electron Microscopy
14%
Coagulation
14%
Procoagulant Platelets
14%
Microparticles
14%
Platelet Response
14%
Calpain Activity
14%
Microvesicles
14%
SB203580
14%
Snake Venom
14%
MAPK Inhibitors
14%
Soluble Collagen
14%
Bleb
14%
Bleb Formation
14%
Aminophospholipids
14%
Scanning Electron Microscopy Analysis
14%
Calpeptin
14%
Microvesiculation
14%
Simultaneous Process
14%
University of Helsinki
14%
Full Aggregation
14%
Platelet Formation
14%
Sequential Activation
14%
Platelet Membrane Glycoprotein VI
14%
Cell Fragments
14%
INIS
maps
100%
phosphorus 38
100%
kinases
100%
adhesion
100%
glycoproteins
100%
collagen
83%
peptides
66%
proteins
50%
membranes
50%
ligands
33%
suspensions
33%
mitogens
33%
fibrinogen
33%
comparative evaluations
16%
snakes
16%
stimulation
16%
units
16%
inhibition
16%
phosphorylation
16%
signals
16%
aggregation
16%
universities
16%
capacity
16%
surfaces
16%
finland
16%
particles
16%
scanning electron microscopy
16%
electron microscopy
16%
venoms
16%
Biochemistry, Genetics and Molecular Biology
Calpain
100%
Thrombocyte Adhesion
100%
Glycoprotein
100%
Platelet
100%
P38 Mitogen-Activated Protein Kinases
100%
Phosphatidylserine
71%
Convulxin
57%
Fibrinogen
28%
Thrombocyte Activation
14%
Electron Microscopy
14%
Evoked Potential
14%
Protease Inhibitor
14%
Thrombopoiesis
14%
Blebbing
14%
Microvesicles
14%
Thrombocyte Membrane
14%
Platelet Glycoprotein
14%
Pharmacology, Toxicology and Pharmaceutical Science
Procoagulant
100%
Glycoprotein VI
100%
Calpain
100%
Mitogen Activated Protein Kinase P38
100%
Phosphatidylserine
83%
Convulxin
66%
Fibrinogen
33%
Microparticle
16%
Electron Microscopy
16%
Aminophospholipid
16%
Proteinase Inhibitor
16%
Calpeptin
16%
Snake Venom
16%
SB 203580
16%